Dihydrodiazepines useful as inhibitors of protein kinases

A compound of formula I:

• wherein
• X1 is a bond, O, NR8, S, SO, or SO2;
• Y1 is O or NR9;
• R1 is H, C1-10aliphatic, C3-10cycloaliphatic, C6-10aryl, 5-10 membered heteroaryl, or 3-10 membered heterocyclyl;
• wherein said R1 is optionally substituted with 0-5 J1;
• provided that when X1 is a bond, R1 is not H;
• R2 is H, C1-10aliphatic, —(C3-10aliphatic)-(C3-10cycloaliphatic), C3-8cycloaliphatic, haloC1-4 aliphatic;
• wherein said R2 is optionally substituted with 0-4 J2;
• each R3, R4, R5, and R6 is independently H, C1-10aliphatic, C3-10cycloaliphatic, C6-10aryl, or 5-10 membered heteroaryl;
• wherein each R3, R4, R5, and R6 is optionally and independently substituted with 0-5 J3, J4, J5, and J6 respectively;
• and
• R7 is H, C(O)R, C(O)OR, or C(O)NRR′, C1-10aliphatic, C3-10cycloaliphatic, C6-10aryl, 5-10 membered heteroaryl, 3-10 membered heterocyclyl, —(C1-6aliphatic)-(C3-10cycloaliphatic), —(C1-6aliphatic)-(C6-10aryl), or —(C1-6aliphatic)-(5-10 membered heteroaryl), or —(C1-6aliphatic)-(3-6 membered heterocyclyl;
• wherein said R7 is optionally substituted with 0-5 J7;
• or
• R3 and R4, together with the carbon atom to which they are attached, optionally form a 3-8 membered saturated or partially unsaturated monocyclic ring containing 0-4 heteroatoms independently selected from O, N, and S;
• said monocyclic ring formed by R3 and R4 is optionally substituted with 0-4 J34;
• R5 and R6, together with the carbon atom to which they are attached, optionally form a 3-8 membered saturated or partially unsaturated monocyclic ring containing 0-4 heteroatoms independently selected from O, N, and S;
• said monocyclic ring formed by R5 and R6 is optionally substituted with 0-4 J56;
• R3 and R5, together with the carbon atoms to which they are attached, optionally form a 3-8 membered saturated or partially unsaturated monocyclic ring containing 0-4 heteroatoms independently selected from O, N, and S;
• said monocyclic ring formed by R3 and R5 is optionally substituted with 0-4 J35;
• R3 and R7, together with the atoms to which they are attached, optionally form a 4-8 membered saturated or partially unsaturated monocyclic ring containing 0-4 heteroatoms independently selected from O, N, and S;
• said monocyclic ring formed by R3 and R7 is optionally substituted with 0-4 J37;
• R5 and R7, together with the atoms to which they are attached, optionally form a 3-8 membered saturated or partially unsaturated monocyclic ring containing 0-4 heteroatoms independently selected from O, N, and S;
• said monocyclic ring formed by R5 and R7 is optionally substituted with 0-4 J57;
• R8 is H, C1-6aliphatic, C3-8cycloaliphatic, C(O)R, C(O)OR, or C(O)NRR′;
• R9 is H or unsubstituted C1-6aliphatic;
• or
• R2 and R9, together with the atoms to which they are attached, optionally form a 5-8 membered aromatic or nonaromatic monocyclic ring containing 2-4 heteroatoms independently selected from O, N, and S;
• said monocyclic ring formed by R2 and R9 is optionally substituted with 0-4 J29;
• each J1 is independently C1-6haloalkyl, halo, NO2, CN, Q, or -Z-Q;
• or, two J1 taken together can optionally form ═O;
• Z is C1-6aliphatic optionally replaced with 0-3 occurrences of —NR—, —O—, —S—, —C(O)—, —C(═NR)—, —C(═NOR)—, —SO—, or —SO2—;
• each Z is optionally substituted with 0-2 JZ;
• Q is H;
• C1-6 aliphatic;
• a 3-8-membered aromatic or nonaromatic monocyclic ring having 0-3 heteroatoms independently selected from O, N, and S;
• or an 7-12 membered aromatic or nonaromatic bicyclic ring system having 0-5 heteroatoms independently selected from O, N, and S;
• each Q is optionally substituted with 0-5 JQ;
• each J2 is halo or haloC1-4 aliphatic;
• each J3, J4, J5, and J6 is independently C1-6 aliphatic, C3-6cycloaliphatic, or —C1-4alkyl)n—V1;
• wherein
• n is O or 1;
• V1 is halo(C1-4 aliphatic), —O(haloC1-4 aliphatic), halo, NO2, CN, OH, OR″, SH, SR″, NH2, NHR″, N(R″)2, COH, COR″, CO2H, CO2R″, CONH2, CONHR″, CONR″2, OCOR″, OCONH2, OCONHR″, OCON(R″)2, NHCOR″, NR″COR″, NHCO2R″, NR″CO2R″, NHCO2H, NR″CO2H, NHCONH2, NHCONHR″, NHCON(R″)2, SO2NH2, SO2NHR″, SO2N(R″)2, NHSO2R″, NR″SO2R″;
• or V1 is a cyclic group selected from C3-6cycloaliphatic, phenyl, 5-6 membered heteroaryl, or 3-6 membered heterocyclyl;
• wherein said cyclic group is optionally substituted with 0-3 JV;
• R″ is unsubstituted C1-4 aliphatic;
• or two of the same J3, J4, J5, or J6, bonded to the same atom, together can optionally form ═O;
• each JZ and JV is independently halo, C1-6 aliphatic, C3-6cycloaliphatic, NO2, CN, —NH2, —NH(C1-4 aliphatic), —N(C1-4 aliphatic)2, —OH, —O(C1-4 aliphatic), —CO2H, —CO2(C1-4 aliphatic), —O(haloC1-4 aliphatic), or halo(C1-4 aliphatic);
• each JQ, J7, J29, J34, J56, J35, J37, and J57 is independently M or —Y-M;
• each Y is independently an unsubstituted C1-6aliphatic optionally replaced with 0-3 occurrences of —NR—, —O—, —S—, —C(O)—, —SO—, or —SO2—;
• each M is independently H, C1-6 aliphatic, C3-6cycloaliphatic, halo(C1-4 aliphatic), —O(haloC1-4 aliphatic), 3-6 membered heterocyclyl, C6-10aryl, halo, NO2, CN, OH, OR′, SH, SR′, NH2, NHR′, N(R′)2, COH, COR′, CO2H, CO2R′, CONH2, CONHR′, CONR′2, OCOR′, OCONH2, OCONHR′, OCON(R′)2, NHCOR′, NR′COR′, NHCO2R′, NR′CO2R′, NHCO2H, NR′CO2H, NHCONH2, NHCONHR′, NHCON(R′)2, SO2NH2, SO2NHR′, SO2N(R′)2, NHSO2R′, or NR′SO2R′, or two M taken together can optionally form ═O;
• R is H or unsubstituted C1-6aliphatic;
• R′ is unsubstituted C1-6aliphatic;
• or two R′ groups, together with the atom to which they are bound, form an unsubstituted 3-8 membered saturated or partially unsaturated monocyclic ring having 0-1 heteroatoms independently selected from O, N, and S.